The Effect of Long-erm Lamivudine Therapy for Chronic Liver Disease due to Hepatitis B Virus.
- Author:
Jin Suk KIM
;
Kwang Hyub HAN
;
Hyo Young CHUNG
;
Sang Hoon AHN
;
Yong Han PAIK
;
Kwan Sik LEE
;
Chae Yoon CHON
;
Young Myoung MOON
- Publication Type:Original Article
- Keywords:
Lamivudine;
HBV DNA breakthrough;
ALT breakthrough;
HBeAg seroconversion;
YMDD
- MeSH:
DNA;
Hepatitis B e Antigens;
Hepatitis B virus*;
Hepatitis B*;
Hepatitis*;
Humans;
Lamivudine*;
Liver Diseases*;
Liver*
- From:The Korean Journal of Hepatology
1999;5(2):97-104
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: We studied to evaluate the virological and biochemical responses to lamivudine and to detect YMDD mutants in patients who received long-erm lamivudine therapy. METHODS: We conducted a one-ear trial of lamivudine in 45 Korean patients with chronic liver disease due to hepatitis B virus. The patients were treated with a single oral average dose of 100 mg of lamivudine every day for 12 months. RESULTS: The suppression of serum HBV DNA was sustained in 77.8% of the patients and the normalization of serum ALT in 80%. The proportions of patients with HBeAg seroconversion were 25%. YMDD mutants were detected in 4 of 8 patients who showed sustained HBV DNA and serum ALT response (n=31) and in 3 of 8 patients who showed HBV DNA or serum ALT breakthrough (n=9). The response to lamivudine therapy in HBeAg-egative patients was excellent. CONCLUSION: Lamivudine therapy resulted in a significant virological and biochemical improvements and were well tolerated. But, YMDD mutants were detected during lamivudine therapy.
